- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. senior Avg
|
- 10-K Annual report
- 4.21 Description of Securities of Seelos Therapeutics, Inc.
- 4.22 Amendment to Convertible Promissory Note
- 23.1 Consent of Independent Registered Public Accounting Firm
- 31.1 Certification of Principal Executive Officer
- 31.2 Certification of Chief Financial Officer
- 32.1 Certification of Chief Executive Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- 32.2 Certification of Chief Financial Officer Pursuant to 18 U.s.c. Section 1350, As Adopted Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- Download Excel data file
- View Excel data file
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statement (Nos. 333-250810, 333-234812 and 333-217036) on Form S-1, registration statement (Nos. 333-261621,333-251356, 333-229491, 333-229490 and 333-223353) on Form S-3 and registration statement (Nos. 333-262224, 333-255670, 333-238562, 333-233305, 333-229846, 333-218368, 333-215419, 333-210040, 333-204748, 333-191680 and 333-182704) on Form S-8 of Seelos Therapeutics, Inc. of our report dated March 4, 2022, with respect to the consolidated balance sheets of Seelos Therapeutics, Inc. as of December 31, 2021 and 2020, and the related statements of operations and comprehensive loss, stockholders’ equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2021, and the related notes, which report appears in the December 31, 2021 annual report on Form 10-K of Seelos Therapeutics, Inc.
/s/ KPMG LLP
Short Hills, New Jersey
March 4, 2022